After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Bausch Health Companies Inc. (BHC) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $8.62. The Bausch Health Companies Inc. has recorded 36,791 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Bausch Health Announces Changes to its Board of Directors.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Stocks Info
BHC belongs to the Healthcare sector of the NYSE while operating in the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $8.62 and fluctuated between $8.71 as its day high and $8.43 as its day low. The current market capitalization of Bausch Health Companies Inc. is $3.16B. A total of 2.56 million shares were traded on the day, compared to an average of 5.89M shares.
In the most recent transaction, Carson Seana sold 292 shares of BHC for 9.32 per share on Feb 28. After the transaction, the EVP, General Counsel now owns 359,185 company shares. In a previous transaction on Jun 01, Bausch Health Companies Inc. sold 4,550,357 shares at 17.05 per share. BHC shares that 10% Owner owns now total 310,449,643.
Among the insiders who sold shares, Bausch Health Companies Inc. disposed of 35,000,000 shares on May 10 at a per-share price of $17.05. This resulted in the 10% Owner holding 315,000,000 shares of BHC after the transaction. In another insider transaction, Spurr Robert sold 1,595 shares at $22.19 per share on Apr 14. Company shares held by the U.S. President-Pharma Business now total 90,506.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for BHC in the last 3 months, the mean price target is $9.00 with high estimates of $10.00 and low estimates of $7.00. In terms of 52-week highs and lows, BHC has a high of $24.26 and a low of $4.00.
As of this writing, BHC has an earnings estimate of $0.91 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $1.11 per share and a lower estimate of $0.73. The company reported an EPS of $0.56 in the last quarter, which was -37.10% lower than expectations of $0.89.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BHC is Overweight with a score of 3.14. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 6 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.
